Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
We read with great interest the work of Zintzaras et al1 in their secondary analyses of cancer outcome in autoimmune rheumatic conditions including systemic lupus erythematous (SLE). Recently, the Systemic Lupus International Collaborating Clinics, in conjunction with the Canadian Network of Improved Outcomes in Systemic Lupus, published an international cohort study of cancer in SLE with 23 centers, with a total sample size of 9547 (an unprecedented number for epidemiologic research in SLE). For all cancers combined, the standardized incidence ratio estimate was 1.15 (95% confidence interval [CI], 1.05-1.27); for all hematologic malignancies, it was 2.75 (95% CI, 2.13-3.49); and for non-Hodgkin lymphoma (NHL), it was 3.64 (95% CI, 2.63-4.93). This thus provides, we believe, the most precise estimates generated to date for NHL occurrence in SLE.2
Bernatsky S, Clarke A, Ramsey-Goldman R. Risk of Lymphoma in Autoimmune Rheumatic Conditions. Arch Intern Med. 2006;166(11):1233–1234. doi:10.1001/archinte.166.11.1233-b
Customize your JAMA Network experience by selecting one or more topics from the list below.